SCHEMBL2027005

SCHEMBL2027005

Cc1cc(Br)cc2c1C(=O)N(Cc1ccc(C#N)cc1)C2

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.39
PIK3R1 P27986 1/20 0.37
PIK3CA P42336 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
HTR2C P28335 1/20 0.37
CA12 O43570 1/20 0.36
CA9 Q16790 1/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC8 Q9BY41 2/20 0.36
HDAC6 Q9UBN7 2/20 0.36
PRMT5 O14744 3/20 0.36
WDR77 Q9BQA1 3/20 0.36
COMT P21964 1/20 0.35
TAS2R8 Q9NYW2 1/20 0.35
CYP19A1 P11511 1/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2022642 0.86 TP53 (0.49) GRM2TP53MAPTHDAC1HDAC8
SCHEMBL13613672 0.86 FNTA (0.42) GRM2HTR2CCYP19A1CYP11B1CYP11B2
SCHEMBL2022812 0.85 KMT2A (0.41) GRM2TP53MAPT
SCHEMBL2025820 0.85 P2RX7 (0.41) GRM2TP53MAPT
SCHEMBL2023569 0.84 MAPK1 (0.42) GRM2TP53MAPTHDAC1HDAC8
SCHEMBL2025050 0.84 PARP1 (0.48) HDAC1HDAC6
SCHEMBL1002356 0.82 P2RX7 (0.39) GRM2MAPT
SCHEMBL2022663 0.82 GRM2 (0.38) GRM2TP53MAPT
SCHEMBL2024998 0.82 GRM2 (0.38) GRM2TP53MAPTPRMT5WDR77
SCHEMBL2027520 0.82 PARK7 (0.46) GRM2HDAC1HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2357169-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators AstraZeneca AB (SE) 2011-08-17 EP disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
WO-2006020879-A1 ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators GRM1, GRIN1, GRM3 GRM2 4/4885PIK3R1 1014/4885PIK3CA 1203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.